ATE389020T1 - Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen - Google Patents

Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen

Info

Publication number
ATE389020T1
ATE389020T1 AT01928775T AT01928775T ATE389020T1 AT E389020 T1 ATE389020 T1 AT E389020T1 AT 01928775 T AT01928775 T AT 01928775T AT 01928775 T AT01928775 T AT 01928775T AT E389020 T1 ATE389020 T1 AT E389020T1
Authority
AT
Austria
Prior art keywords
polypeptides
compounds
diagnosis
treatment
methods
Prior art date
Application number
AT01928775T
Other languages
English (en)
Inventor
Ajay Bhatia
Peter Probst
Erika Stromberg
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE389020T1 publication Critical patent/ATE389020T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4568—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01928775T 2000-04-21 2001-04-23 Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen ATE389020T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19885300P 2000-04-21 2000-04-21
US21975200P 2000-07-20 2000-07-20

Publications (1)

Publication Number Publication Date
ATE389020T1 true ATE389020T1 (de) 2008-03-15

Family

ID=26894210

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928775T ATE389020T1 (de) 2000-04-21 2001-04-23 Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen

Country Status (8)

Country Link
US (2) US20030175700A1 (de)
EP (2) EP2192128A3 (de)
AT (1) ATE389020T1 (de)
AU (1) AU2001255596A1 (de)
CA (1) CA2407114A1 (de)
DE (1) DE60133190T2 (de)
ES (1) ES2303525T3 (de)
WO (1) WO2001081379A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
EP1105489A1 (de) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nukleinsäuren kodierend für pomp91a aus chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP2172214A3 (de) 1999-03-12 2011-03-16 Aventis Pasteur Limited Chlamydia-Antigene und entsprechende DNA-Fragmente sowie Verwendungen davon
WO2000066739A2 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (de) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1282718B1 (de) 2000-05-08 2006-12-20 Sanofi Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
CN101184504A (zh) 2005-03-31 2008-05-21 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
AU2008331800A1 (en) * 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
US10131693B2 (en) 2008-10-20 2018-11-20 Gwangju Institute Of Science And Technology Bipodal-peptide binder
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
WO2011118496A1 (ja) * 2010-03-23 2011-09-29 和光純薬工業株式会社 クラミジア・トラコマティス検出用プライマー及びプローブ、並びにこれを用いたクラミジア・トラコマティスの検出方法
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
CA2850228A1 (en) * 2011-09-30 2013-04-04 The University Of British Columbia Chlamydia antigen compositions and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4118469A (en) * 1976-04-27 1978-10-03 Research Corporation Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU)
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4497899A (en) * 1982-04-12 1985-02-05 Abbott Laboratories Immunoassay for Chlamydia trachomatis antigens
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0359789B1 (de) 1988-01-21 1993-08-04 Genentech, Inc. Verstärkung und nachweis von nukleinsäuresequenzen
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0348725A3 (de) 1988-06-29 1990-10-24 Miles Inc. Sorten-spezifische Epitode von Chlamydia trachomatis und Antikörper, die diese erkennen
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
EP1001032A3 (de) 1989-08-18 2005-02-23 Chiron Corporation Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5616326A (en) 1990-01-25 1997-04-01 The University Court Of The University Of Glasgow Recombinant canine adenovirus 2 (CAV-2)
US5166053A (en) * 1990-02-23 1992-11-24 Miles Inc. Specimen adequacy control for chlamydia assays
JP3018553B2 (ja) * 1990-05-08 2000-03-13 日立化成工業株式会社 クラミジア・トラコマティス抗体測定方法及びクラミジア・トラコマティス感染症診断用製剤
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5725863A (en) * 1991-09-06 1998-03-10 The United States Of America As Represented By The Secretary Of Agriculture Polypeptides useful in prevention of chlamydia infection
US5518913A (en) 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
AU669000B2 (en) 1992-09-18 1996-05-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthetic peptide vaccine for chlamydia trachomatis
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
CN100365017C (zh) 1994-09-20 2008-01-30 日立化成工业株式会社 肺炎衣原体抗原多肽
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (de) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. VERBESSERTER VERFAHREN ZUR HERSTELLUNG VON cDNA-SEQUENZEN MIT VOLLER LÄNGER
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
GB9516293D0 (en) 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
WO1998002546A2 (en) 1996-07-12 1998-01-22 University Of Manitoba Dna immunization against chlamydia infection
US6464979B1 (en) 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
EP1133572A4 (de) 1998-11-12 2005-06-15 Univ California Genomsequenz von chlamydia pneumoniae
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) * 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
US6432916B1 (en) * 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6166177A (en) * 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
WO2000066739A2 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (de) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1282718B1 (de) 2000-05-08 2006-12-20 Sanofi Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
US20040137007A1 (en) 2004-07-15
CA2407114A1 (en) 2001-11-01
US7384638B2 (en) 2008-06-10
EP2192128A2 (de) 2010-06-02
DE60133190T2 (de) 2009-04-02
US20030175700A1 (en) 2003-09-18
EP2192128A3 (de) 2010-09-22
EP1278855B1 (de) 2008-03-12
WO2001081379A3 (en) 2002-09-19
DE60133190D1 (de) 2008-04-24
ES2303525T3 (es) 2008-08-16
AU2001255596A1 (en) 2001-11-07
WO2001081379A2 (en) 2001-11-01
EP1278855A2 (de) 2003-01-29

Similar Documents

Publication Publication Date Title
DE60133190D1 (de) Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
DE69942426D1 (de) Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
DE60130468D1 (de) Zusammensetzungen und verfahren zur behandlung von chlamydia-infektionen
NZ518917A (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO1998042740A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2003041560A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
ATE324445T1 (de) Verbindungen und verfahren zur diagnose von tuberkulose
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO2000000615A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO1998016645A3 (en) Compounds and methods for diagnosis of tuberculosis
DE60125537D1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO2001085949A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
EP0834567A3 (de) Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Babesia microti Infektion
WO2002053016A3 (en) Compounds and methods for the diagnosis and treatment of babesia infection
WO2003020108A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2001085947A3 (en) Compounds and methods for the diagnosis and treatment of babesia microti infection

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties